Welcome to the winter edition of European Oncology and Haematology. At the end of another year in which the field of oncology has reported new standards of care and improved outcomes in numerous types of cancer, we feature a range of topical articles covering several therapeutic areas.
This edition begins with a fascinating editorial from Francesca Vinchi on the role of free haem and iron in shaping macrophage plasticity towards a pro-inflammatory phenotype, which may have important therapeutic implications for patients with sickle cell disease. In our expert interviews, Reinhard Dummer discusses the findings of the landmark COLUMBUS clinical trial and their implications for the treatment of BRAF-mutant melanoma, Miguel Marcao provides an update on the clinical development of lenvatinib for the treatment of hepatocellular carcinoma and Jason Lester explains the benefits and limitations of proton-beam therapy in the treatment of solid tumours.
Case reports are an important addition to scientific journals as they can raise awareness of rare subtypes of common diseases, as well as side effects of frequently used medications. In this issue, Petricevic et al. present a case of epidermal growth factor receptor (EGFR) mutations in a patient with small cell lung cancer, an unusual finding as such mutations are generally associated with non-small cell lung cancers.
Despite advances in the treatment of numerous cancers, the prognosis for patients with metastatic or locally advanced, non-resectable bladder cancer remains poor with platinum-based chemotherapy. Jong and Samoi present a much-needed review of the latest advances in immune checkpoint inhibition and other novel therapeutic options in this patient population. By contrast, the treatment landscape of multiple myeloma has been transformed in recent years thanks to the introduction of novel agents and new combination therapies. Minnema and Gavriatopoulou review the remaining challenges and unmet needs in the treatment of this malignancy, with a focus on tailoring treatment to the individual patient. Finally, Janssens and Wakelin present a mini-review that compares centrifugal and membrane therapeutic plasma exchange and the factors influencing treatment decisions.
Foreword – European Oncology & Haematology. 2018;14(2):75
Welcome to the winter edition of European Oncology and Haematology. At the end of another year in which the field of oncology has reported new standards of care and improved outcomes in numerous types of cancer, we feature a range of topical articles covering several therapeutic areas. This edition begins with a fascinating editorial from […]
Shaping Macrophage Plasticity with Iron – Towards a New Therapeutic Approach
Reticulo-endothelial (RES) macrophages are central for the regulation of iron homeostasis. These cells have the ability to handle a high amount of haemoglobin-derived iron, released after senescent red blood cell phagocytosis. Eventually, iron is exported to the bloodstream through the only known iron exporter, ferroportin, and is utilised to support the production of new red […]
BRAF-mutant Melanoma – The COLUMBUS Trial
Melanoma represents a significant and increasing public health burden, and is the largest cause of skin cancer-related deaths.1 Approximately half of advanced (unresectable or metastatic) melanomas have a mutation in the BRAF gene, with V600E being the most common mutation, leading to the therapeutic use of BRAF inhibitors.2 However, the response rates with single-agent BRAF […]
Lenvatinib in Hepatocellular Carcinoma
Liver cancer is the second leading cause of cancer-related death, and has limited treatment options and a poor prognosis.1 Mortality owing to liver cancer has increased in the past 20 years, with a reported incidence of 841,080 cases per year.2 Hepatocellular carcinoma (HCC) represents about 90% of primary liver cancer cases.1 Multiple single agent and […]
Proton Beam Therapy
Proton beam therapy is a type of radiotherapy that employs a high energy beam of protons rather than high energy X-rays to deliver a dose of radiotherapy for patients with cancer.1 The UK has been involved in the development of proton beam therapy; a specialist eye service at Clatterbridge, Merseyside, UK, was the first hospital-based […]
Treatment Resistant de novo Epidermal Growth Factor Receptor (EGFR)-mutated Small Cell Lung Cancer
Small cell lung cancer (SCLC) is an aggressive high-grade bronchogenic carcinoma with neuroendocrine features occurring predominantly in current or former smokers.1 Despite initial sensitivity to platinum-based chemotherapy, almost all patients will relapse and develop resistance to conventional treatment.2 At present, no effective targeted treatment strategies have been approved in SCLC.3 In contrast, oncogenic driver mutations […]
Novel Options in Metastatic and Non-surgically Curable Bladder Cancer
Bladder cancer is the ninth most common cancer worldwide, with an estimated 430,000 new cases and 165,000 deaths in 2012.1 More than 90% of bladder cancers are of urothelial cell origin and the remaining histological subtypes include either pure forms of histological variants, such as squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcoma, or […]
Optimising Treatment in Relapsed, Refractory Multiple Myeloma
The past decade has experienced a shift in the treatment landscape for multiple myeloma (MM), with the introduction of novel agents and new combination therapies which have improved survival outcomes for patients across all disease settings.1 These advances in treatment strategy have extended median relative survival to 7.7 years in patients with myeloma aged 65 […]
Centrifugal and Membrane Therapeutic Plasma Exchange – A Mini-review
Therapeutic plasma exchange (TPE) is an extracorporeal technique that involves separating a large volume of a patient’s plasma from the cellular components of the blood and replacing it with appropriate fluids.1 In patients with conditions that are induced and/or exacerbated by pathologic factors and toxins circulating in the plasma, TPE can help eliminate symptoms or […]